The clinical management of bladder cancer (BC) has become an increasing challenge due
to high incidence rate of BC, malignant behavior of cancer cells and drug resistance. The …

Bladder cancer (BCa) is one of the 10 most common cancers with high morbidity and
mortality worldwide. Long noncoding RNAs (lncRNAs), a large class of noncoding RNA …

Bladder cancer (BC) is the most common malignant tumor in the urinary system, and its early
diagnosis is conducive to improving clinical prognosis and prolonging overall survival time …

Bladder cancer (BC) is a common and serious type of cancer that ranks among the top ten
most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the …

Several reports over the last 10 years provided evidence that long noncoding RNAs
(lncRNAs) are often altered in bladder cancers. lncRNAs are longer than 200 nucleotides …

Bladder cancer is a common disease associated with high rates of morbidity and mortality.
Although immunotherapy approaches such as adoptive T-cell therapy and immune …

Aberrant expression of long non-coding RNAs (lncRNAs) has been regarded as a critical
component in bladder cancer (BC) and lncRNAs have been associated with BC …

The mortality and morbidity that characterize bladder cancer compel this malignancy into the
category of hot topics in terms of biomolecular research. Therefore, a better knowledge of …

Cell‐free long non‐coding RNAs (lncRNAs) are stably present in urine and can serve as
non‐invasive biomarkers for cancer. We aimed to identify signatures of lncRNAs in urine for …

The advent of novel high-throughput sequencing methods has facilitated identification of
non-coding RNAs with fundamental roles in cellular biological and pathological conditions …